Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, describes current research investigating antibodies targeting α-synuclein in patients with Parkinson’s disease. The SPARK trial (NCT03318523) of cinpanemab failed to meet its primary endpoint but the secondary endpoint was met in the PASADENA trial (NCT03100149) of prasinezumab. Prof. Stocchi additionally highlights the PADOVA study (NCT04777331), a continuation of the PASADENA trial, as well as novel compounds targeting the lysosome. This interview took place at the 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.